Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MacroGenics, Inc.
Anthony DeBoer, head of business development at Synaffix, joined the company in 2014 and has helped develop a platform technology business model in the antibody drug conjugate space, where Synaffix has become one of the leading technology providers enabling best-in-class therapeutic candidates.
The second quarter has already seen the approval of Gamida Cell’s cell therapy Omisirge, and with the help of Biomedtracker, Scrip highlights 10 of the more interesting new drug approvals due in the next three months.
The antibody-drug conjugate field is beginning to reach its full potential and big pharma’s attention has been caught.
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
- Drug Delivery
- Drug Discovery Tools
- Other Names / Subsidiaries
- Raven Biotechnologies
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.